According to news from foreign authoritative medical websites, at the European Cancer Congress, an immunotherapeutic drug is likely to become a “regulator rewriter†for cancer treatment because of its amazing efficacy.
Immunotherapy destroys cancer cells by activating the immune system.
In a head and neck cancer trial, patients treated with the immunotherapeutic drug nivolumab had a longer survival than patients receiving chemotherapy. In another trial, nivolumab combined with another drug narrowed the tumor in patients with advanced kidney cancer.
In this trial involving more than 350 patients with head and neck cancer, 36% of patients treated with the immunotherapeutic drug nivolumab survived after one year of treatment, while those who received chemotherapy survived only 17% a year later, and immunotherapy Less side effects. The study was published in the New England Journal of Medicine.
For those patients who test positive for HPV (human papillomavirus), the effect is more pronounced. The average survival of these patients treated with nivolumab was 9.1 months, while the average survival of chemotherapy was only 4.4 months.
The survival rate of advanced head and neck cancer is very low. In general, patients with advanced or refractory head and neck cancer will not survive for more than 6 months.
Double hit cancer
Another early trial data of 94 patients with advanced renal cancer showed that the combination of nivolumab and ipilimumab was effective in reducing tumors in 40% of patients. One in 10% of these 40% of patients have no signs of cancer residual. Only 5% of patients receiving standard treatment had a smaller tumor.
In the UK, approximately 12,000 people are diagnosed with kidney cancer each year, with an average of 12 people dying every day.
Peter's Anti-Cancer Tour
"I didn't think I would get advanced cancer, because I haven't felt pain all the time," said 64-year-old Peter Waite. "There is no negative impact on me. I really feel a little embarrassed."
Peter had kidney cancer and lung cancer. He recovered kidney cancer recurrence a few years after his recovery. In early 2015, he participated in a clinical trial and began to receive combined immunotherapy (a combination of nivolumab and ipilimumab).
The doctor once said that he probably has three to five years of life.
Instead of receiving chemotherapy, he received four months of immunotherapeutic treatment. The treatment showed little side effects. He could still continue his work as a motor technician during treatment.
Concealed Hinges,Screw-On Hinges,Concealed Door Hinges,Concealed Cabinet Hinges
Ningbo Hengchieh Locking Technology Co., Ltd. , https://www.hengchieh.com